Please login to the form below

Not currently logged in
Email:
Password:

veno-occlusive disease

This page shows the latest veno-occlusive disease news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Pfizer's antibody drug for leukaemia

NICE rejects Pfizer's antibody drug for leukaemia

After the publication of the INO-VATE data oncologists welcomed having an alternative that is generally easier to tolerate than chemo, although Besponsa has been linked to veno-occlusive disease (VOD)

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... The US regulator has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    The Italy-based pharma company had applied for European approval of defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation therapy,

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    3, 080. Cosmo Technologies/ Salix Pharmaceuticals. Merger (tax inversion)    . Portfolio of treatments for gastrointestinal disease and disorders. ... 360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics